Ascentage Pharma (AAPG) announced that its novel next-generation BTK-targeted protein degrader, APG-3288, has received the IND clearance from the U.S. Food and Drug Administration and is poised to enter a clinical study in patients with relapsed/refractory B-cell malignancies. This clearance officially opens the chapter on Ascentage Pharma’s clinical development in the field of targeted degradation and marks another major expansion to the company’s global innovative pipeline, the company said. This is a global, multicenter, open-label Phase I study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma to Present at J.P. Morgan Healthcare Conference
- Ascentage Pharma initiated with a Buy at Lucid Capital
- Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025
- Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025
- Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax